FPC
LAB icon

Falcon Point Capital’s Standard BioTools LAB Stock Holding History

Falcon Point Capital’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-40,504
Closed -$164K – 118
2017
Q2 		$164K Sell
40,504
-157
-0.4% -$744 0.02% 109
2017
Q1 		$231K Buy
40,661
+1,238
+3% +$7.84K 0.03% 109
2016
Q4 		$287K Buy
39,423
+1,366
+4% +$8.58K 0.04% 100
2016
Q3 		$176K Buy
+38,057
New +$350K 0.03% 102

Other funds holding LAB

LCS
Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Falcon Point Capital's LAB Position: Q3 2017 in Review

Falcon Point Capital sold out of Standard BioTools (LAB) in Q3 2017, closing a stake of 40,504 shares — an estimated $164K sold.

Falcon Point Capital first reported a position in LAB in Q3 2016 and held it in 4 quarters. The position peaked at $287K in Q4 2016. 80 funds tracked by Wall St. Rank hold LAB as of Q3 2017.

  • Falcon Point Capital reported no remaining Standard BioTools position as of Q3 2017 after selling out during the quarter.
  • Falcon Point Capital sold 40,504 Standard BioTools shares in Q3 2017, an estimated $164K.
  • Falcon Point Capital first reported a position in Standard BioTools in Q3 2016 and held it in 4 quarters.
  • Falcon Point Capital's Standard BioTools position peaked at $287K in Q4 2016.
  • 80 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2017.

Based on Falcon Point Capital's 13F filing for Q3 2017, filed 14 Nov 2017.